A fully replication-competent adenovirus vector with enhanced oncolytic properties

Cancer Gene Therapy

Volumn 17, Issue 11, 2010, Pages 761-770

  Toth, K ^a   Kuppuswamy, M ^a   Shashkova, E V ^a   Spencer, J F ^a   Wold, W S M ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

replicating; tumor; virotherapy; virus

Indexed keywords

ADENOVIRUS DEATH PROTEIN; ADENOVIRUS VECTOR; ANTINEOPLASTIC AGENT; CIDOFOVIR 3 HEXADECYLOXYPROPYL ESTER; INGN 007; KD 3; ONCOLYTIC ADENOVIRUS; ONYX 015; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG INHIBITION; FEMALE; GENE DELETION; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; LUNG CANCER; MELANOMA; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; SURVIVAL TIME; TUMOR GROWTH; VIRUS REPLICATION;

ADENOVIRIDAE; ANIMALS; CELL LINE, TUMOR; CRICETINAE; FEMALE; GENE THERAPY; GENETIC VECTORS; HUMANS; MICE; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; VIRUS REPLICATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ADENOVIRIDAE; MUS MUSCULUS; ONYX;

EID: 77958096107     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2010.33     Document Type: Article

References (35)

1. Cattaneo R, Miest T, Shashkova EV, Barry MA. Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded. Nat Rev Microbiol 2008; 6: 529-540.
2. Bischoff Jr, Kirn DH, Williams A, Heise C, Horn S, Muna M et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996; 274: 373-376.
3. Freytag SO, Rogulski KR, Paielli DL, Gilbert JD, Kim JH. A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene, and radiotherapy. Hum Gene Ther 1998; 9: 1323-1333.
4. Rodriguez R, Schuur ER, Lim HY, Henderson GA, Simons JW, Henderson DR. Prostate attenuated replication compe-tent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res 1997; 57: 2559-2563.
5. Yu DC, Chen Y, Seng M, Dilley J, Henderson DR. The addition of adenovirus type 5 region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts. Cancer Res 1999; 59: 4200-4203.
6. Lichtenstein DL, Wold WSM. Experimental infections of humans with wild-type adenoviruses and with replication-competent adenovirus vectors: replication, safety, and transmission. Cancer Gene Ther 2004; 11: 819-829.
7. Lin E, Nemunaitis J. Oncolytic viral therapies. Cancer Gene Ther 2004; 11: 643-664.
8. Jia H, Kling J. China offers alternative gateway for experimental drugs. Nat Biotechnol 2006; 24: 117-118.
9. Doronin K, Toth K, Kuppuswamy M, Krajcsi P, Tollefson AE, Wold WSM. Overexpression of the ADP (E3-11.6K) protein increases cell lysis and spread ofadenovirus. Virology 2003; 305: 378-387.
10. Berk AJ. Recent lessons in gene expression, cell cycle control, and cell biology from adenovirus. Oncogene 2005; 24: 7673-7685.
11. Gonzalez R, Huang W, Finnen R, Bragg C, Flint SJ. Adenovirus E1B 55-kilodalton protein is required for both regulation of mRNA export and efficient entry into the late phase of infection in normal human fibroblasts. J Virol 2006; 80: 964-974.
12. Vaillancourt M, Atencio I, Quijano E, Howe JA, Ramachandra M. Inefficient killing of quiescent human epithelial cells by replicating adenoviruses: potential implica-tions for their use as oncolytic agents. Cancer Gene Ther 2005; 12: 691-698.
13. Barton KN, Paielli D, Zhang Y, Koul S, Brown SL, Lu M et al. Second-generation replication-competent oncolytic adenovirus armed with improved suicide genes and ADP gene demonstrates greater efficacy without increased toxicity. Mol Ther 2006; 13: 347-356.
14. Wein LM, Wu JT, Kirn DH. Validation and analysis of a mathematical model of a replication-competent oncolytic virus for cancer treatment: implications for virus design and delivery. Cancer Res 2003; 63: 1317-1324.
15. Doronin K, Toth K, Kuppuswamy M, Ward P, Tollefson AE, Wold WSM. Tumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein. J Virol 2000; 74: 6147-6155.
16. Toth K, Tarakanova V, Doronin K, Ward P, Kuppuswamy M, Locke JL et al. Radiation increases the activity of oncolytic adenovirus cancer gene therapy vectors that overexpress the ADP (E3-11.6K) protein. Cancer Gene Ther 2003; 10: 193-200.
17. Lichtenstein DL, Spencer JF, Doronin K, Patra D, Meyer J, Shashkova EV et al. An acute toxicology study with INGN 007, an oncolytic adenovirus vector, in mice and permissive Syrian hamsters; comparisons with wild-type Ad5 and a replication-defective adenovirus vector. Cancer Gene Ther 2009; 16: 644-654.
18. Ying B, Toth K, Spencer JF, Meyer J, Tollefson AE, Patra D et al. INGN 007, an oncolytic adenovirus vector, replicates in Syrian hamsters but not mice: comparison of biodistribution studies. Cancer Gene Ther 2009; 16: 625-637.
19. Barker DD, Berk AJ. Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection. Virology 1987; 156: 107-121.
20. Tollefson AE, Kuppuswamy M, Shashkova EV, Doronin K, Wold WSM. Preparation and titration of CsCl-banded adenovirus stocks. Methods Mol Med2007; 130: 223-235.
21. Kuppuswamy M, Spencer JF, Doronin K, Tollefson AE, Wold WS, Toth K. Oncolytic adenovirus that overproduces ADP and replicates selectively in tumors due to hTERT promoter-regulated E4 gene expression. Gene Therapy 2005; 12: 1608-1617.
22. Toth K, Spencer JF, Dhar D, Sagartz JE, Buller RM, Painter GR et al. Hexadecyloxypropyl-cidofovir CMX001, prevents adenovirus-induced mortality in a permissive, immunosuppressed animal model. Proc Natl Acad Sci USA 2008; 105: 7293-7297.
23. Toth K, Spencer JF, Tollefson AE, Kuppuswamy M, Doronin K, Lichtenstein DL et al. Cotton rat tumor model for the evaluation of oncolytic adenoviruses. Hum Gene Ther 2005; 16: 139-146.
24. Dhar D, Spencer JF, Toth K, Wold WSM. Effect of preexisting immunity on oncolytic adenovirus vector INGN 007 antitumor efficacy in immunocompetent and immunosuppressed Syrian hamsters. J Virol 2009; 83: 2130-2139.
25. Dhar D, Spencer JF, Toth K, Wold WS. Pre-existing immunity and passive immunity to adenovirus 5 prevents toxicity caused by an oncolytic adenovirus vector in the Syrian hamster model. Mol Ther 2009; 17: 1724-1732.
26. Thomas MA, Spencer JF, La Regina MC, Dhar D, Tollefson AE, Toth K et al. Syrian hamster as a per-missive immunocompetent animal model for the study of oncolytic adenovirus vectors. Cancer Res 2006; 66: 1270-1276.
27. Thomas MA, Spencer JF, Toth K, Sagartz JE, Phillips N, Wold WSM. Immunosuppression enhances oncolytic adenovirus replication and anti tumor efficacy in the Syrian hamster model. Mol Ther 2008; 16: 1665-1673.
28. Hartline CB, Gustin KM, Wan WB, Ciesla SL, Beadle Jr, Hostetler KY et al. Ether lipid-ester prodrugs of acyclic nucleoside phosphonates: activity against adenovirus replication in vitro. J Infect Dis 2005; 191: 396-399.
29. Dilley J, Reddy S, Ko D, Nguyen N, Rojas G, Working P et al. Oncolytic adenovirus CG7870 in combination with radiation demonstrates synergistic enhancements of antitumor efficacy without loss of specificity. Cancer Gene Ther 2005; 12: 715-722.
30. Huang P, Watanabe M, Kaku H, Kashiwakura Y, Chen J, Saika T et al. Direct and distant antitumor effects of a telomerase-selective oncolytic adenoviral agent OBP-301, in a mouse prostate cancer model. Cancer Gene Ther 2008; 15: 315-322.
31. Ryan PC, Jakubczak JL, Stewart DA, Hawkins LK, Cheng C, Clarke LM et al. Antitumor efficacy and tumor-selective replication with a single intravenous injection ofOAS403, an oncolytic adenovirus dependent on two prevalent alterations in human cancer. Cancer Gene Ther 2004; 11: 555-569.
32. Spencer JF, Sagartz JE, Wold WSM, Toth K. New pancreatic carcinoma model for studying oncolytic adeno-viruses in the permissive Syrian hamster. Cancer Gene Ther 2009; 16: 912-922.
33. Alemany R. Cancer selective adenoviruses. Mol Aspects Med 2007; 28: 42-58.
34. Kumar S, Gao L, Yeagy B, Reid T. Virus combinations and chemotherapy for the treatment of human cancers. Curr Opin Mol Ther 2008; 10: 371-379.
35. Lichtenstein DL, Toth K, Doronin K, Tollefson AE, Wold WSM. Functions and mechanisms of action of the adenovirus E3 proteins. Int Rev Immunol 2004; 23: 75-111.